160 related articles for article (PubMed ID: 34490741)
21. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
22. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
Højberg PV; Vilsbøll T; Rabøl R; Knop FK; Bache M; Krarup T; Holst JJ; Madsbad S
Diabetologia; 2009 Feb; 52(2):199-207. PubMed ID: 19037628
[TBL] [Abstract][Full Text] [Related]
23. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.
Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK
Bone; 2020 Nov; 140():115553. PubMed ID: 32730920
[TBL] [Abstract][Full Text] [Related]
24. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA
Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636
[TBL] [Abstract][Full Text] [Related]
25. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
[TBL] [Abstract][Full Text] [Related]
26. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Christensen M; Vedtofte L; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2011 Dec; 60(12):3103-9. PubMed ID: 21984584
[TBL] [Abstract][Full Text] [Related]
27. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans.
Veedfald S; Vedtofte L; Skov-Jeppesen K; Deacon CF; Hartmann B; Vilsbøll T; Knop FK; Christensen MB; Holst JJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665480
[TBL] [Abstract][Full Text] [Related]
28. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Chia CW; Carlson OD; Kim W; Shin YK; Charles CP; Kim HS; Melvin DL; Egan JM
Diabetes; 2009 Jun; 58(6):1342-9. PubMed ID: 19276444
[TBL] [Abstract][Full Text] [Related]
29. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
30. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of alimentary insulin secretion despite similar gastric inhibitory peptide (GIP) responses in juvenile obesity.
Heptulla RA; Tamborlane WV; Cavaghan M; Bronson M; Limb C; Ma YZ; Sherwin RS; Caprio S
Pediatr Res; 2000 May; 47(5):628-33. PubMed ID: 10813588
[TBL] [Abstract][Full Text] [Related]
32. Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
Meier JJ; Nauck MA; Siepmann N; Greulich M; Holst JJ; Deacon CF; Schmidt WE; Gallwitz B
Metabolism; 2003 Dec; 52(12):1579-85. PubMed ID: 14669159
[TBL] [Abstract][Full Text] [Related]
33. Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.
Christensen MB; Lund AB; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
J Endocr Soc; 2020 Sep; 4(9):bvaa097. PubMed ID: 32904711
[TBL] [Abstract][Full Text] [Related]
34. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
35. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
Martinussen C; Veedfald S; Dirksen C; Bojsen-Møller KN; Svane MS; Wewer Albrechtsen NJ; van Hall G; Kristiansen VB; Fenger M; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2020 Jun; 318(6):E956-E964. PubMed ID: 32182123
[TBL] [Abstract][Full Text] [Related]
36. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes.
Bergmann NC; Lund A; Gasbjerg LS; Jørgensen NR; Jessen L; Hartmann B; Holst JJ; Christensen MB; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2019 Jul; 104(7):2953-2960. PubMed ID: 30848791
[TBL] [Abstract][Full Text] [Related]
37. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).
Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V
Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963
[TBL] [Abstract][Full Text] [Related]
38. Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH
Gasbjerg LS; Bari EJ; Stensen S; Hoe B; Lanng AR; Mathiesen DS; Christensen MB; Hartmann B; Holst JJ; Rosenkilde MM; Knop FK
Diabetes Obes Metab; 2021 Jan; 23(1):68-74. PubMed ID: 32886401
[TBL] [Abstract][Full Text] [Related]
39. GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes.
Heimbürger SMN; Hoe B; Nielsen CN; Bergman NC; Skov-Jeppesen K; Hartmann B; Holst JJ; Dela F; Overgaard J; Størling J; Vilsbøll T; Dejgaard TF; Havelund JF; Gorshkov V; Kjeldsen F; Færgeman NJ; Madsen MR; Christensen MB; Knop FK
J Clin Endocrinol Metab; 2022 Nov; 107(12):3261-3274. PubMed ID: 36111559
[TBL] [Abstract][Full Text] [Related]
40. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance.
Wang S; Oestricker LZ; Wallendorf MJ; Sterl K; Dunai J; Kilpatrick CR; Patterson BW; Reeds DN; Wice BM
PLoS One; 2018; 13(2):e0192441. PubMed ID: 29466430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
